Edgestream Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Sell	5,810 -1,438	-20%	-$489K	0.06%	500
2025 Q4	$2.88M	Buy	+7,248	New	+$3.21M	0.08%	438
2025 Q1	–	Sell	-13,806	Closed	-$3.25M	–	826
2024 Q4	$3.25M	Buy	+13,806	New	+$3.63M	0.14%	291
2024 Q3	–	Sell	-6,052	Closed	-$1.47M	–	824
2024 Q2	$1.47M	Sell	6,052 -17,303	-74%	-$2.73M	0.07%	426
2024 Q1	$3.49M	Buy	23,355 +15,394	+193%	+$2.57M	0.17%	198
2023 Q4	$1.52M	Buy	7,961 +5,536	+228%	+$943K	0.11%	309
2023 Q3	$429K	Sell	2,425 -9,120	-79%	-$1.74M	0.03%	628
2023 Q2	$2.19M	Buy	11,545 +3,872	+50%	+$768K	0.2%	159
2023 Q1	$1.54M	Buy	+7,673	New	+$1.61M	0.17%	197
2022 Q3	–	Sell	-10,785	Closed	-$1.57M	–	443
2022 Q2	$1.57M	Buy	10,785 +6,783	+169%	+$962K	0.12%	248
2022 Q1	$653K	Sell	4,002 -17,985	-82%	-$2.74M	0.05%	383
2021 Q4	$3.73M	Buy	21,987 +5,566	+34%	+$1.03M	0.23%	136
2021 Q3	$3.1M	Buy	16,421 +4,740	+41%	+$889K	0.19%	182
2021 Q2	$1.98M	Buy	+11,681	New	+$1.71M	0.12%	221